eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
8/2003
vol. 7
 
Share:
Share:
abstract:

Biochemotherapy of mestastic melanoma – clinical experience and perspective analysis

Jakub Żołnierek
,
Joanna Paprocka-Langiewicz
,
Krzysztof Leśniewski-Kmak
,
Przemysław Langiewicz
,
Tomasz Sarosiek
,
Wojciech Pawlak

Współcz Onkol (2003) vol. 7, 8 (611-618)
Online publish date: 2003/11/05
View full text Get citation
 
Metastatic cutaneous melanoma as a chemoresistant neoplasm is a great challenge to the contemporary oncology. In this article we analyze recent results of melanoma treatment with combined chemotherapy and cytokines (biochemotherapy) on basis of both own experience and medical literature. We try to estimate the real indications for biochemotherapy in the treatment of metastatic melanomas and show some of new points of diagnostics and practical use.
Between December 1996 and March 2003 in the Oncology Department of the Central Clinical Hospital of the Military Medical Institute 39 patients with metastatic melanomas received CVD chemotherapy (dacarbazine 800 mg/m2 d. 1, cisplatin 20 mg/m2 d. 1–4 and vinblastine 1.6 mg/m2 d. 4 and 5) intravenously combined with interleukin-2 (9 mlnU/m2 d. 1–4) and interferon alpha (5 mlnU/m2 d. 1–5) administered subcutaneously (BIO). We planned sequential treatment schedule of three cycles of CVD (d. 1–5, 22–26, 43–47) and three cycles of BIO (d. 6–10, 17–21, 27–31). Median age was 44 (22–62). Before biochemotherapy ten patients (26%) had metastasectomy (NED before treatment), twenty (51%) had metastases only in lymph nodes, soft tissue and lungs. Toxicities were recorded according WHO criteria for all patients receiving at least one cycle of CVD chemotherapy and one immunotherapy (BIO), that is 39 (100%), responses were recorded for 25 patients (64%) with measurable disease, and time to progression (TTP), progression free survival (PFS) and overall survival (OS) for 34 patients (87%). Non-hematological grade 3 or 4 toxicity was moderate: fever – 7 pts (17.7%), nausea and vomiting – 3 pts (7.7%), anorexia – 3 pts (7.7%), flu-like syndrome – 3 pts (7.7%). Grade 3 or 4 neutropenia was confirmed in 9 pts (23.1%), thrombocytopenia in 5 pts (12.8%) and anemia in 3 pts (7.7%). We obtained 6 CR (24%) and 8 PR (32%). Median TTP (month) was 6.5 (2–49), PFS of 7 (2–49) and OS of 11.5 (5–64).
keywords:

melanoma, biochemotherapy, interleukin-2

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.